glp-1 drugs manufacturers suppliers distributors 2023-2025 Pipeline Update: August 2025 - Prime Therapeutics Manufacturers Must Adapt to Growing
Description
It is also Merck's position that the reported pancreatitis with sitagliptin therapy is due to the increased risk of pancreatitis in type 2 diabetes rather than a consequence of drug therapy (18), mimicking the Amylin Corporation position
Beinaglutide was approved in China in 2016 for T2DM and also reduced BMI in overweight patients [13]
It also had a positive effect on body weight, with participants on IcoSema losing almost 8 pounds compared to those taking basal-bolus insulin who gained roughly 7 pounds
Robert Kushner Mike Haney: So getting back to that we talked about obesity as a disease, and it's a disease in some part because our bodies were not evolved to live in such a food-rich, calorie-rich environment
Morningstar projects that Novo Nordisk and Eli Lilly will be at the forefront of the GLP-1 drug market in the coming years
Back Royal Society of Chemistry (2025) 'Harnessing hormones for health Taking GLP from research to reality', Chemistry World Webinar
